10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

NASDAQ:TXG • US88025U1097

18.88 USD
-0.31 (-1.62%)
At close: Feb 20, 2026
18.88 USD
0 (0%)
After Hours: 2/20/2026, 8:08:31 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

TXG gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. TXG has a great financial health rating, but its profitability evaluates not so good. TXG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year TXG has reported negative net income.
  • TXG had a positive operating cash flow in the past year.
  • In the past 5 years TXG always reported negative net income.
  • In the past 5 years TXG reported 4 times negative operating cash flow.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M -400M -500M

1.2 Ratios

  • TXG has a Return On Assets of -7.43%. This is comparable to the rest of the industry: TXG outperforms 50.00% of its industry peers.
  • TXG has a Return On Equity of -9.72%. This is comparable to the rest of the industry: TXG outperforms 55.17% of its industry peers.
Industry RankSector Rank
ROA -7.43%
ROE -9.72%
ROIC N/A
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 68.90%, TXG belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
  • TXG's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.43%
GM growth 5Y-3.01%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TXG has more shares outstanding
  • Compared to 5 years ago, TXG has more shares outstanding
  • There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 4.77 indicates that TXG is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.77, TXG belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
  • TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.77
ROIC/WACCN/A
WACC10.88%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.48 indicates that TXG has no problem at all paying its short term obligations.
  • The Current ratio of TXG (4.48) is better than 70.69% of its industry peers.
  • TXG has a Quick Ratio of 4.06. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
  • TXG has a Quick ratio of 4.06. This is in the better half of the industry: TXG outperforms 72.41% of its industry peers.
Industry RankSector Rank
Current Ratio 4.48
Quick Ratio 4.06
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.71%, which is quite impressive.
  • The Revenue has been growing slightly by 5.25% in the past year.
  • Measured over the past years, TXG shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.80% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, TXG will show a small growth in Revenue. The Revenue will grow by 5.48% on average per year.
EPS Next Y-122.99%
EPS Next 2Y-28.8%
EPS Next 3Y25.99%
EPS Next 5Y27.8%
Revenue Next Year-3.48%
Revenue Next 2Y1.78%
Revenue Next 3Y3.92%
Revenue Next 5Y5.48%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TXG. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TXG is valued a bit cheaper than 74.14% of the companies in the same industry.
Industry RankSector Rank
P/FCF 29.26
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • TXG's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.8%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TXG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

10X GENOMICS INC-CLASS A

NASDAQ:TXG (2/20/2026, 8:08:31 PM)

After market: 18.88 0 (0%)

18.88

-0.31 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)05-06
Inst Owners107.99%
Inst Owner Change1.53%
Ins Owners1.6%
Ins Owner Change-0.79%
Market Cap2.39B
Revenue(TTM)642.82M
Net Income(TTM)-76.32M
Analysts69.52
Price Target18.43 (-2.38%)
Short Float %14.28%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.5%
Min EPS beat(2)24.4%
Max EPS beat(2)174.61%
EPS beat(4)3
Avg EPS beat(4)47.23%
Min EPS beat(4)-34.43%
Max EPS beat(4)174.61%
EPS beat(8)6
Avg EPS beat(8)27.95%
EPS beat(12)7
Avg EPS beat(12)13.27%
EPS beat(16)8
Avg EPS beat(16)1.94%
Revenue beat(2)2
Avg Revenue beat(2)13.16%
Min Revenue beat(2)3.54%
Max Revenue beat(2)22.78%
Revenue beat(4)4
Avg Revenue beat(4)11.15%
Min Revenue beat(4)2.51%
Max Revenue beat(4)22.78%
Revenue beat(8)5
Avg Revenue beat(8)4.76%
Revenue beat(12)9
Avg Revenue beat(12)4.17%
Revenue beat(16)11
Avg Revenue beat(16)2.67%
PT rev (1m)1.52%
PT rev (3m)22.22%
EPS NQ rev (1m)3.15%
EPS NQ rev (3m)13.49%
EPS NY rev (1m)13.8%
EPS NY rev (3m)30.14%
Revenue NQ rev (1m)0.96%
Revenue NQ rev (3m)3.34%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)3.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.72
P/FCF 29.26
P/OCF 26.99
P/B 3.04
P/tB 3.34
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)0.65
FCFY3.42%
OCF(TTM)0.7
OCFY3.71%
SpS5.07
BVpS6.2
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.43%
ROE -9.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.9%
FCFM 12.72%
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.43%
GM growth 5Y-3.01%
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 23.81%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.48
Quick Ratio 4.06
Altman-Z 4.77
F-Score5
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
EPS Next Y-122.99%
EPS Next 2Y-28.8%
EPS Next 3Y25.99%
EPS Next 5Y27.8%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%
Revenue Next Year-3.48%
Revenue Next 2Y1.78%
Revenue Next 3Y3.92%
Revenue Next 5Y5.48%
EBIT growth 1Y21.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-244.89%
EBIT Next 3Y-16.12%
EBIT Next 5YN/A
FCF growth 1Y226.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.97%
OCF growth 3YN/A
OCF growth 5YN/A

10X GENOMICS INC-CLASS A / TXG FAQ

Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?

ChartMill assigns a fundamental rating of 4 / 10 to TXG.


What is the valuation status of 10X GENOMICS INC-CLASS A (TXG) stock?

ChartMill assigns a valuation rating of 2 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.


Can you provide the profitability details for 10X GENOMICS INC-CLASS A?

10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.


Can you provide the financial health for TXG stock?

The financial health rating of 10X GENOMICS INC-CLASS A (TXG) is 8 / 10.